Azacytidine - Nanexa
Alternative Names: Azacitidine - Nanexa; NEX-18; NEX-18aLatest Information Update: 28 May 2024
At a glance
- Originator Nanexa
- Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action Antimetabolites; DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Myelodysplastic syndromes
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in Sweden (Parenteral, Injection)
- 12 Apr 2022 Nanexa terminates its phase I trial in Myelodysplastic syndromes in Sweden as sponsor plans for a reformulation of NEX 18 before the clinical phase of the project will be resumed (NCT05048498)
- 22 Jun 2021 Nanexa has patent protection for PharmaShell® in South Korea